Development of an automatic rapid test system for blood diagnostics and immunoassays

AESKU. Group has received funding from the European Union's Fund for Region Growth 2014 – 2020 Program to develop an automated platform for the automation of Point-Of-Care (POC) Tests. Read more...

Clinical Performance of AESKU.RAPID SARS-CoV-2 Antigen Test to detect Delta variant (B1.617.2)

Biomex has carried out a study to establish the performance of the AESKU.RAPID SARS-CoV-2 Antigen Test in detecting the SARS-CoV-2 Delta variant.

The testing was carried out with four infected and confirmed patients over a period of up to 9 days after onset of symptoms.A total of 26 nasal swabs were tested with the AESKU.RAPID SARS-CoV-2 Antigen Test and simultaneously analyzed through a PCR Test. The collection of the swabs was carried out in Germany with European subjects.

All samples up to Ct-values of 36.15 have been positive with the AESKU.RAPID SARS-CoV-2 Antigen Test. In some cases, even samples which have been negative in the PCR gave a slight positive result with the AESKU.RAPID SARS-CoV-2 Antigen Test. Thus, the requirement stipulated by the Paul-Ehrlich-Institut (PEI), that samples within the first 7 days after onset of symptoms should be detected positive, has been fulfilled.

In conclusion, the sensitivity of AESKU.RAPID SARS-CoV-2 Antigen Test to detect the delta variant is very high, as it detected all positive samples confirmed by the PCR.

Download the Complete Study (PDF Document)